Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OXIGENE INC. (OXGN) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (238)	8/20/2001 11:45:35 AM
From: nigel bates	Read Replies (2) \| Respond to of 273

Announced 11 minutes before the event? Great news management... Anyway, listening to the call (FWIW), key points (so far) were that: - There have been NO drug related fatalities - BMS's P1 trials are ongoing & open for recruitment; have not been halted by the FDA. - As for time taken over P1 trials, they repeatedly stressed that they are able to monitor drug activity (by monitoring tumour blood flow) as well as toxicity during P1 trials. They suggested that this will give BMS sufficient data to be able to conduct quicker P11 trials. - In the 100 patients in the P1 trials conducted by Oxigene, there were 2 cardiac events, both of which were "at or above' the MTD. The dose limiting toxicities were ataxia & tumour pain, not cardiac events. - They are prevented by their agreement with BMS from commenting on the BMS trials "We cannot specifically comment on results from BMS trials, either positive, or negative. nig